Case Study | March 21, 2013

EDC And Getting Ready For Migration

Source: DATATRAK International, Inc.

As the biopharmaceutical industry continues its transition to electronic data capture (EDC), the days of paper-based clinical trials are numbered. Driving this trend are factors such as lengthy study start-up time, high incidence of queries and drawn-out database lock, all linked to inefficient paper-based processes. DATATRAK ONE™ addresses these challenges by improving data quality and making them visible faster, enabling real-time safety reviews, and allowing sponsors and contract research organizations (CROs) to better assess the safety profile of a drug as it is being developed.

These well-established benefits of EDC have resulted in an estimated 60% of new clinical trial starts using the technology, with even higher rates of adoption in pivotal studies. But for companies still on the sidelines, still conducting clinical trials on paper, a short overview of DATATRAK ONE™ uEDCTM features and a case study on the paper-to-EDC migration process are presented. The case study is from a major biotechnology company, which experienced the following positive outcomes:

  • Immediate elimination of queries of omission
  • Proactive handling of serious adverse events (SAEs)
  • Significantly shorter time to database lock

For full access to this content, please Register or Sign In.

Access Content EDC And Getting Ready For Migration
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.